Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma

International Journal of Oncology

Volumn 46, Issue 1, 2015, Pages 113-122

  Lam, Sze Kwan ^a   Li, Yuan Yuan ^a   Zheng, Chun Yan ^a   Ho, James Chung Man ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Arsenic trioxide; Mesothelioma; Thymidylate synthase; Transcription factor E2F1; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ORGANOARSENIC DERIVATIVE; OXIDE; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR E2F1;

ANIMAL; BAGG ALBINO MOUSE; DOWN REGULATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL LINE, TUMOR; DOWN-REGULATION; E2F1 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; OXIDES; THYMIDYLATE SYNTHASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84917678228     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2716     Document Type: Article

References (40)

1. Borasio P, Berruti A, Bille A, et al: Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg 33: 307-313, 2008.
2. Abakay A, Abakay O, Tanrikulu AC, et al: Effects of treatment regimens on survival in patients with malignant pleural mesothelioma. Eur Rev Med Pharmacol Sci 17: 19-24, 2013.
3. Rahman L, Voeller D, Rahman M, et al: Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 5: 341-351, 2004.
4. Bunn PA Jr: Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). Semin Oncol 29: 17-22, 2002.
5. Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G and Peters GJ: Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 66: 431-438, 2003.
6. Lustgarten DE, Deshpande C, Aggarwal C, et al: Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma. J Thorac Oncol 8: 469-477, 2013.
7. Mairinger F, Vollbrecht C, Halbwedl I, et al: Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma. J Thorac Oncol 8: 644-653, 2013.
8. Fennell DA and Rudd RM: Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 5: 354-362, 2004.
9. Kumana CR, Au WY, Lee NS, et al: Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol 58: 521-526, 2002.
10. Lam SK, Mak JC, Zheng CY, Li YY, Kwong YL and Ho JC: Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma. Int J Oncol 44: 2093-2102, 2014.
11. Subbarayan PR, Lee K and Ardalan B: Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 in vitro re-sensitizing cells to 5-FU. Anticancer Res 30: 1157-1162, 2010.
12. Eguchi R, Fujimori Y, Takeda H, et al: Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells. J Cell Physiol 226: 762-768, 2011.
13. You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N and Nguyen DM: Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg 147: 508-516, 2014.
14. Slee EA and Lu X: Requirement for phosphorylation of P53 at Ser312 in suppression of chemical carcinogenesis. Sci Rep 3: 3105, 2013.
15. Li YY, Lam SK, Mak JC, Zheng CY and Ho JC: Erlotinibinduced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer. Lung Cancer 81: 354-361, 2013.
16. Pressacco J, Mitrovski B, Erlichman C and Hedley DW: Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res 55: 1505-1508, 1995.
17. Kousparou CA, Yiacoumi E, Deonarain MP and Epenetos AA: Generation of a selectively cytotoxic fusion protein against p53 mutated cancers. BMC Cancer 12: 338, 2012.
18. Shen ZX, Chen GQ, Ni JH, et al: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
19. Aballay LR, Diaz Mdel P, Francisca FM and Munoz SE: Cancer incidence and pattern of arsenic concentration in drinking water wells in Cordoba, Argentina. Int J Environ Health Res 22: 220-231, 2012.
20. Naujokas MF, Anderson B, Ahsan H, et al: The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem. Environ Health Perspect 121: 295-302, 2013.
21. de The H, Le Bras M and Lallemand-Breitenbach V: The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol 198: 11-21, 2012.
22. Cai X, Shen YL, Zhu Q, et al: Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14: 262-270, 2000.
23. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG and Waxman S: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94: 2102-2111, 1999.
24. Mahieux R, Pise-Masison C, Gessain A, et al: Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 98: 3762-3769, 2001.
25. Park WH, Seol JG, Kim ES, et al: Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 60: 3065-3071, 2000.
26. Shim MJ, Kim HJ, Yang SJ, Lee IS, Choi HI and Kim T: Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase. J Biochem Mol Biol 35: 377-383, 2002.
27. Wang ZG, Rivi R, Delva L, et al: Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 92: 1497-1504, 1998.
28. Gorgoulis VG, Zacharatos P, Mariatos G, et al: Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 198: 142-156, 2002.
29. Zacharatos P, Kotsinas A, Evangelou K, et al: Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas. J Pathol 203: 744-753, 2004.
30. Tsuji AB, Sogawa C, Sugyo A, et al: Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts. Nucl Med Biol 36: 379-388, 2009.
31. Erculj N, Kovac V, Hmeljak J, Franko A, Dodic-Fikfak M and Dolzan V: The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. Pharmacogenet Genomics 22: 58-68, 2012.
32. Kitagawa K, Kotake Y and Kitagawa M: Ubiquitin-mediated control of oncogene and tumor suppressor gene products. Cancer Sci 100: 1374-1381, 2009.
33. Nuvoli B, Santoro R, Catalani S, et al: CELLFOOD induces apoptosis in human mesothelioma and colorectal cancer cells by modulating p53, c-myc and pAkt signaling pathways. J Exp Clin Cancer Res 33: 24, 2014.
34. Kitamura A, Matsushita K, Takiguchi Y, et al: Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma. Cancer Sci 102: 1366-1373, 2011.
35. Ghaffari SH, Momeny M, Bashash D, Mirzaei R, Ghavamzadeh A and Alimoghaddam K: Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkbeta-dependent induction of hTERT due to down-regulation of Pin1 transcription. Hematology 17: 198-206, 2012.
36. Song W, Ma Y, Wang J, Brantley-Sieders D and Chen J: JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer. Cancer Res 74: 2444-2454, 2014.
37. Yedjou C, Tchounwou P, Jenkins J and McMurray R: Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol 3: 28, 2010.
38. Jin HO, Yoon SI, Seo SK, et al: Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem Pharmacol 72: 1228-1236, 2006.
39. Luo M, Lu Z, Sun H, et al: Nuclear entry of active caspase-3 is facilitated by its p3-recognition-based specific cleavage activity. Cell Res 20: 211-222, 2010.
40. Lam SK, Li YY, Zheng CY, Leung LL and Ho JC: E2F1 downregulation by arsenic trioxide in lung adenocarcinoma. Int J Oncol 45: 2033-2043, 2014.